HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Post-Pandemic Stocks

1,032.682

+15.9631.57%

Number of Gainers:7

Number of Losers:8

Number of Flat:3

PE:- -

High:1,051.942

Open:1,016.598

Low:1,010.116

Close:1,016.720

Loading ...

China Traditional Chinese Medicine Holdings Co. Limited Conducted Annual General Meeting

CSPC Pharmaceutical Group Ltd. Announces Appointment of Ms. LI Quan to Nomination Committee

JD Health International Stock Advances 2.1% in Hong Kong

Ping An Healthcare and Technology Co. Ltd. Conducted Annual General Meeting

Nature's Sunshine Shares Fall Premarket After Shanghai Fosun Sells Stake

BRIEF-Sino Biopharmaceutical Says LM-108 Included In Breakthrough Therapy Designation

Sino Biopharmaceutical's LM-108 Monoclonal Antibody Enters Breakthrough Therapy Designation Process for Advanced Gastric Cancer Treatment in China

Sino Biopharmaceutical - Lm-108 Included in Breakthrough Therapy Designation Process by Center for Drug Evaluation of Nmpa

THOMSON REUTERS

Kintor Pharmaceutical Ltd: DR. Youzhi Tong Has Stepped Down as Chairman

THOMSON REUTERS

Kintor Pharmaceutical Ltd. Announces New Leadership for Nomination Committee

BYD Electronic (International) Stock Slides 1.6% in Hong Kong

Ludwig Enterprises Inc. Appoints Garth Lees-Rolfe as New Independent Director

China Traditional Chinese Medicine Holdings Co. Announces NMPA Acceptance of New Drug Application for Yushuda Tablets, Initiating Regulatory Review

China Traditional Chinese Medicine - Nmpa Acceptance of New Drug Application of Yushuda Tablets

THOMSON REUTERS

Yichang HEC Changjiang Pharmaceutical Co. Ltd. Discloses Internal Dealings Involving Equity Swaps and Commercial Paper in Privatisation Effort

JD Health International Stock Climbs 1.9% in Hong Kong

CSPC Pharmaceutical Group Expands Subsidiary Operations in China

Shanghai Junshi Biosciences Raises HK$1.04 Billion Following Share Sale; Shares Gain 7%

MT Newswires Live

CSPC Pharmaceutical Group Ltd. Secures Drug Registration Approval for Meloxicam Injection (III) in China

CSPC Pharmaceutical - Meloxicam Injection Obtains Drug Registration Approval

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1515/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1515","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"Post-Pandemic Stocks","latestPrice":1032.6821,"timestamp":1751011731311,"preClose":1016.7195,"halted":0,"volume":900765822,"delay":0,"changeRate":0.0157,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":15.962646,"latestTime":"06-27 16:00:00","open":1016.59753,"high":1051.9421,"low":1010.11584,"amount":5669452515,"amplitude":0.041138,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1751247000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1750987800000,1750996800000],[1751000400000,1751011200000]],"pbRate":1.752375,"peRate":23.4179,"turnoverRate":0.011967,"increases":7,"decrements":9,"flats":2,"marketCap":706905967872,"floatMarketCap":585402001280},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":1051.9421,"amplitude":0.041138,"preClose":1016.7195,"low":1010.11584,"pbRate":"1.752375","latestPrice":1032.6821,"volume":900765822,"delay":0,"open":1016.59753,"prevYearClose":787.97723,"prevWeekClose":974.914,"prevMonthClose":975.506,"prevQuarterClose":870.015,"fiveDayClose":974.914,"twentyDayClose":975.506,"sixtyDayClose":881.168,"secType":"PLATE","market":"HK","turnoverRate":0.011967,"peRate":23.4179,"marketCap":706905967872,"floatMarketCap":585402001280,"timestamp":1751011731311,"nameCN":"Post-Pandemic Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":7,"down":8,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2546106307","title":"China Traditional Chinese Medicine Holdings Co. Limited Conducted Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2546106307","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546106307?lang=en_us&edition=fundamental","pubTime":"2025-06-27 19:03","pubTimestamp":1751022228,"startTime":"0","endTime":"0","summary":"China Traditional Chinese Medicine Holdings Co. Limited held its Annual General Meeting on 27 June 2025. During the meeting, several proposals were reviewed, including the re-election of Mr. HUANG Hao, Mr. YU Tze Shan Hailson, and Mr. QIN Ling as directors of the company. All proposals were approved by the shareholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Traditional Chinese Medicine Holdings Co. Limited published the original content used to generate this news brief on June 27, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250627:nNDL980Zv6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00570","BK1191","BK1515","BK1606"],"gpt_icon":0},{"id":"2546071523","title":"CSPC Pharmaceutical Group Ltd. Announces Appointment of Ms. LI Quan to Nomination Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2546071523","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546071523?lang=en_us&edition=fundamental","pubTime":"2025-06-27 17:14","pubTimestamp":1751015683,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group Ltd. has announced a change in the composition of its Nomination Committee. Ms. LI Quan, an independent non-executive director, has been appointed as a member of the committee, effective 27 June 2025. The Nomination Committee now consists of Mr. CAI Dong Chen , Mr. WANG Bo, Mr. CHEN Chuan, and Ms. LI Quan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief on June 27, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250627:nNDL9nTRw9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0067412154.USD","LU1226287875.USD","BK1515","IE00BZ08YT58.USD","LU1993786604.SGD","LU1152091168.USD","IE0008368742.USD","LU0326950275.SGD","IE00B031HY20.USD","LU1226288170.HKD","LU1008478684.HKD","BK1191","IE00B5MMRT66.SGD","01093","IE0008369823.USD","LU0880133367.SGD","LU1807302812.USD","LU1226288253.USD","LU1951186391.HKD","LU0140636845.USD","LU0072913022.USD","LU1960683339.HKD","SG9999004220.SGD","LU1226287792.SGD","LU1152091754.HKD","LU0501845795.SGD","IE00BZ08YR35.GBP","IE00B543WZ88.USD","IE00BZ08YS42.EUR","LU1226287529.USD","BK1521"],"gpt_icon":0},{"id":"2546905847","title":"JD Health International Stock Advances 2.1% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2546905847","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546905847?lang=en_us&edition=fundamental","pubTime":"2025-06-27 16:30","pubTimestamp":1751013000,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of JD Health International Inc. advanced 2.1% to 43.30 Hong Kong dollars on what proved to be an all-around poor trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.2% to 24284.15.This was the stock's sixth consecutive day of gains.JD Health International Inc. closed 0.3% below its 52-week high of HK$43.45, which the company achieved June 17.Trading volume totaled 10.0 million shares, compared to the 50-day average of 10.5 million shares.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["86618","BK1571","BK1589","BK1515","BK1247","06618","LU0051755006.USD","BK1615","BK1583","BK1591","BK1142","LU0456827905.SGD"],"gpt_icon":1},{"id":"2546877507","title":"Ping An Healthcare and Technology Co. Ltd. Conducted Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2546877507","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546877507?lang=en_us&edition=fundamental","pubTime":"2025-06-26 19:54","pubTimestamp":1750938855,"startTime":"0","endTime":"0","summary":"Ping An Healthcare and Technology Co. Ltd. held its annual general meeting on 26 June 2025. During the meeting, several proposals were presented and voted upon. A proposal to grant a general mandate to the Directors to buy back shares was approved. Additionally, a proposal to extend the authority given to the Directors to issue additional shares, representing the number bought back, was also approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ping An Healthcare and Technology Co. Ltd. published the original content used to generate this news brief on June 26, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nNDL71d8vf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","LU1781817850.SGD","LU1064131003.USD","601318","BK0207","BK0012","LU2495084118.USD","LU1655091616.SGD","LU1064130708.USD","LU0456827905.SGD","LU0405327494.USD","BK0175","BK0196","LU1997245094.SGD","BK0070","SG9999002463.SGD","LU0326950275.SGD","LU1146622755.USD","BK1247","BK0183","LU1820825898.SGD","LU1997245177.USD","LU1969619763.USD","LU2213484517.USD","LU1580142542.USD","LU2148510915.USD","BK1571","LU1997244956.HKD","LU0456846285.SGD","BK0032","LU2289578879.USD","LU0039217434.USD","IE0005HP3H50.USD","LU1934453819.USD","LU2328871848.SGD","LU0405327148.USD","BK1615","BK1219","LU0051755006.USD","BK1617","BK0188","BK0187","BK1142","01833","BK0028","LU0047713382.USD","LU1979443071.USD"],"gpt_icon":0},{"id":"2546782734","title":"Nature's Sunshine Shares Fall Premarket After Shanghai Fosun Sells Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2546782734","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546782734?lang=en_us&edition=fundamental","pubTime":"2025-06-26 19:29","pubTimestamp":1750937340,"startTime":"0","endTime":"0","summary":"Nature's Sunshine Products shares fell sharply in premarket trading Thursday after one of the nutritional supplements maker's biggest investors sold its stake at steep discount.Nature's Sunshine said a secondary public offering of up to 2.85 million shares held by a unit of Shanghai Fosun Pharmaceutical was priced at $12 apiece, well below Wednesday's closing price of $14.84.Shares of the Lehi, Utah, company were recently down 16% to $12.50 in premarket trading.Fosun received the shares, representing a more than 15% stake in Nature's Sunshine, as part of a 2014 transaction that formed a pair of joint ventures in which Fosun held 20% interests.Nature's Sunshine said it will be required to buy Fosun's stake in the ventures in connection with the offering, adding that it expects to fund the roughly $7 million purchase with cash on hand and drawings under its credit facility.The company said it also may buy back up to $15 million worth of the shares Fosun is selling.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0012","02196","BK1230","BK0175","BK0188","BK1543","BK1113","BK0060","00656","BK0183","BK4183","BK1191","BK0196","00509","600196","BK0187","BK1515","BK0096","BK1593","NATR","BK0028"],"gpt_icon":0},{"id":"2546985781","title":"BRIEF-Sino Biopharmaceutical Says LM-108 Included In Breakthrough Therapy Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2546985781","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546985781?lang=en_us&edition=fundamental","pubTime":"2025-06-26 18:32","pubTimestamp":1750933960,"startTime":"0","endTime":"0","summary":"BRIEF-Sino Biopharmaceutical Says LM-108 Included In Breakthrough Therapy Designation June 26  - Sino Biopharmaceutical Ltd 1177.HK:LM-108 INCLUDED IN BREAKTHROUGH THERAPY DESIGNATION PROCESS BY CENTER FOR DRUG EVALUATION OF NMPAFurther company coverage: 1177.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nFWN3SS0UJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YT58.USD","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","BK1191","BK1515","01177","BK1589","BK1521"],"gpt_icon":0},{"id":"2546331789","title":"Sino Biopharmaceutical's LM-108 Monoclonal Antibody Enters Breakthrough Therapy Designation Process for Advanced Gastric Cancer Treatment in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2546331789","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546331789?lang=en_us&edition=fundamental","pubTime":"2025-06-26 18:04","pubTimestamp":1750932248,"startTime":"0","endTime":"0","summary":"Sino Biopharmaceutical's LM-108 Monoclonal Antibody Enters Breakthrough Therapy Designation Process for Advanced Gastric Cancer Treatment in China. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief on June 26, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nNDL8Q8D9J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YR35.GBP","BK1515","IE00BZ08YT58.USD","BK1191","BK1521","01177","IE00BZ08YS42.EUR","BK1589"],"gpt_icon":0},{"id":"2546786184","title":"Sino Biopharmaceutical -  Lm-108 Included in Breakthrough Therapy Designation Process by Center for Drug Evaluation of Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2546786184","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546786184?lang=en_us&edition=fundamental","pubTime":"2025-06-26 17:57","pubTimestamp":1750931861,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nFWN3SS0UJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","IE00BZ08YR35.GBP","BK1589","BK1515","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","01177","BK1521"],"gpt_icon":0},{"id":"2546885827","title":"Kintor Pharmaceutical Ltd: DR. Youzhi Tong Has Stepped Down as Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2546885827","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546885827?lang=en_us&edition=fundamental","pubTime":"2025-06-26 17:06","pubTimestamp":1750928782,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nFWN3SS0UB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","BK1161","BK1574","09939"],"gpt_icon":0},{"id":"2546200398","title":"Kintor Pharmaceutical Ltd. Announces New Leadership for Nomination Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2546200398","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546200398?lang=en_us&edition=fundamental","pubTime":"2025-06-26 17:02","pubTimestamp":1750928552,"startTime":"0","endTime":"0","summary":"Kintor Pharmaceutical Ltd. has announced changes to its Nomination Committee effective June 26, 2025. Dr. Youzhi Tong has stepped down as chairman and member of the committee. Ms. Geqi Wei has been appointed as a member, and Dr. Michael Min Xu is now the chairman. The committee now includes two independent non-executive directors and one non-executive director, enhancing its diversity.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kintor Pharmaceutical Ltd. published the original content used to generate this news brief on June 26, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nNDL4Vw6C7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1515","BK1161","09939"],"gpt_icon":0},{"id":"2546202651","title":"BYD Electronic (International)  Stock Slides 1.6% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2546202651","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546202651?lang=en_us&edition=fundamental","pubTime":"2025-06-26 16:32","pubTimestamp":1750926720,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of BYD Electronic  Co. Ltd. slipped 1.6% to 31.35 Hong Kong dollars on what proved to be an all-around grim trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.6% to 24325.40.The stock's fall snapped a four-day winning streak.BYD Electronic  Co. Ltd. closed 49% short of its 52-week high of HK$61.55, which the company achieved Feb. 13.Despite its losses, the stock outperformed some of its competitors, as Times Universal Group Holdings Ltd. fell 3.1%.Trading volume totaled 9.0 million shares, compared to the 50-day average of 19.5 million shares.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","LU0274383008.USD","LU0348767384.USD","BK1607","BK1149","00285","BK1580","BK1582","BK1540","LU0348766576.USD","BK1589","BK1504"],"gpt_icon":0},{"id":"2546240487","title":"Ludwig Enterprises Inc. Appoints Garth Lees-Rolfe as New Independent Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2546240487","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546240487?lang=en_us&edition=fundamental","pubTime":"2025-06-26 01:41","pubTimestamp":1750873312,"startTime":"0","endTime":"0","summary":"Ludwig Enterprises Inc. has appointed Garth Lees-Rolfe as a new independent director, effective June 23, 2025. Lees-Rolfe brings over 19 years of experience in finance and strategic financial planning. He is currently the CFO of ABLi Therapeutics, Inc., and has held previous roles at Inhibikase Therapeutics, Inc. and F-Star, Inc. He has also worked at Ernst & Young and holds qualifications from the Queensland University of Technology and Kaplan Professional.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ludwig Enterprises Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 25, 2025","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nNDLnSRwS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IKT","01177","BK1191","BK1515","LUDG","BK1589","IE00BZ08YR35.GBP","BK4139","BK1521","IE00BZ08YS42.EUR","IE00BZ08YT58.USD"],"gpt_icon":0},{"id":"2546421119","title":"China Traditional Chinese Medicine Holdings Co. Announces NMPA Acceptance of New Drug Application for Yushuda Tablets, Initiating Regulatory Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2546421119","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546421119?lang=en_us&edition=fundamental","pubTime":"2025-06-25 18:50","pubTimestamp":1750848605,"startTime":"0","endTime":"0","summary":"China Traditional Chinese Medicine Holdings Co. Announces NMPA Acceptance of New Drug Application for Yushuda Tablets, Initiating Regulatory Review. China Traditional Chinese Medicine Holdings Co. Limited has announced that the National Medical Products Administration  of China has accepted the new drug application for Yushuda Tablets, a Class 1.1 innovative traditional Chinese medicine developed by its subsidiary, Sinopharm Group Tongjitang  Pharmaceutical Co., Ltd. The acceptance marks the start of a series of regulatory review procedures, including technical evaluation and on-site inspection. Yushuda Tablets have shown significant efficacy in treating symptoms associated with qi stagnation and mild-to-moderate depression. While this is a promising development, the timeline for final approval remains uncertain, and shareholders are advised to exercise caution.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nNDL7TXdX5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","LU1115378108.SGD","BK1606","BK1515","00570","BK1500","01099","LU0640798160.USD","BK1197"],"gpt_icon":0},{"id":"2546211944","title":"China Traditional Chinese Medicine  -  Nmpa Acceptance of New Drug Application of Yushuda Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2546211944","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546211944?lang=en_us&edition=fundamental","pubTime":"2025-06-25 18:47","pubTimestamp":1750848464,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nFWN3SS06S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1606","BK1515","BK1191","00570"],"gpt_icon":0},{"id":"2546904042","title":"Yichang HEC Changjiang Pharmaceutical Co. Ltd. Discloses Internal Dealings Involving Equity Swaps and Commercial Paper in Privatisation Effort","url":"https://stock-news.laohu8.com/highlight/detail?id=2546904042","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546904042?lang=en_us&edition=fundamental","pubTime":"2025-06-25 17:22","pubTimestamp":1750843365,"startTime":"0","endTime":"0","summary":"Yichang HEC Changjiang Pharmaceutical Co. Ltd. Discloses Internal Dealings Involving Equity Swaps and Commercial Paper in Privatisation Effort. Yichang HEC ChangJiang Pharmaceutical Co., Ltd. has disclosed internal dealings under Rule 22 of the Hong Kong Code on Takeovers and Mergers. CICC Wealth Investment Limited, an exempt principal trader connected with the Offeror, executed transactions involving other types of securities on 24 June 2025. The dealings were made for its own account, with a sale of 1,200 shares and a purchase of 1,200 shares. CICC Wealth Investment Limited is ultimately owned by China International Capital Corporation Limited.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Yichang Hec Changjiang Pharmaceutical Co. L","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nNDL1lNqZD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0276","BK1191","BK1515","601995","01558"],"gpt_icon":0},{"id":"2546432294","title":"JD Health International Stock Climbs 1.9% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2546432294","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546432294?lang=en_us&edition=fundamental","pubTime":"2025-06-25 16:40","pubTimestamp":1750840800,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of JD Health International Inc. advanced 1.9% to 42.00 Hong Kong dollars on what proved to be an all-around positive trading session for the Hong Kong stock market, with the Hang Seng Index rising 1.2% to 24474.67.This was the stock's fourth consecutive day of gains.JD Health International Inc. closed 3.3% short of its 52-week high of HK$43.45, which the company achieved June 17.Trading volume totaled 8.1 million shares, compared to the 50-day average of 11.4 million shares.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06618","86618","BK1591","BK1615","BK1571","BK1247","BK1589","LU0051755006.USD","LU0456827905.SGD","BK1515","BK1142","BK1583"],"gpt_icon":1},{"id":"2545400066","title":"CSPC Pharmaceutical Group Expands Subsidiary Operations in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2545400066","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545400066?lang=en_us&edition=fundamental","pubTime":"2025-06-24 17:46","pubTimestamp":1750758418,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group Ltd., a leading entity in the pharmaceutical industry, has several key subsidiaries actively engaged in the manufacturing and sales of pharmaceutical products. Among these subsidiaries are CSPC NBP Pharmaceutical Co., Ltd., CSPC Ouyi Pharmaceutical Co., Ltd., and CSPC Zhongnuo Pharmaceutical  Co., Ltd. Notably, CSPC Zhongnuo is a non-wholly-owned subsidiary, with the Group holding a 99.393% stake. Meanwhile, CSPC Zhongqi Pharmaceutical Technology  Co., Ltd., focuses on research and development within the pharmaceutical sector. These subsidiaries, based in the People's Republic of China, play a crucial role in advancing the Group's mission to provide high-quality pharmaceutical products and innovative research solutions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nNDLc7pH7J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","IE00B031HY20.USD","IE00B543WZ88.USD","LU1226288170.HKD","LU1951186391.HKD","LU0880133367.SGD","LU0067412154.USD","LU1152091754.HKD","IE0008369823.USD","LU0326950275.SGD","LU1008478684.HKD","LU1226287792.SGD","01093","LU0140636845.USD","IE00BZ08YT58.USD","LU1993786604.SGD","LU1226287875.USD","IE00BZ08YR35.GBP","LU1226287529.USD","SG9999004220.SGD","BK1521","IE0008368742.USD","BK1515","LU1960683339.HKD","IE00B5MMRT66.SGD","LU1152091168.USD","LU0072913022.USD","LU0501845795.SGD","LU1807302812.USD","IE00BZ08YS42.EUR","LU1226288253.USD"],"gpt_icon":0},{"id":"2545498865","title":"Shanghai Junshi Biosciences Raises HK$1.04 Billion Following Share Sale; Shares Gain 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2545498865","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545498865?lang=en_us&edition=fundamental","pubTime":"2025-06-23 15:30","pubTimestamp":1750663818,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences  completed the sale of 41 million H shares in a transaction valued at around HK$1.04 billion, according to a Friday bourse filing.Shares gained about 7% in Monday's afternoon trade.The cancer medicine developer sold the shares at HK$25.35 apiece and proceed raised will be used to advance the development of its therapies, it said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01877","BK1583","BK1161","BK1515"],"gpt_icon":0},{"id":"2545451377","title":"CSPC Pharmaceutical Group Ltd. Secures Drug Registration Approval for Meloxicam Injection (III) in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2545451377","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545451377?lang=en_us&edition=fundamental","pubTime":"2025-06-23 08:03","pubTimestamp":1750637004,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group Ltd. has announced that its Meloxicam Injection  has received drug registration approval from the National Medical Products Administration of the People's Republic of China. This product is indicated for the treatment of moderate to severe pain in adults and is the first intravenously administered nanocrystal product approved in China. Utilizing novel nanotechnology, this formulation allows for high-dose, rapid intravenous administration, offering a rapid onset and long-lasting analgesic effects for acute postoperative pain. This approval marks a significant advancement for CSPC in the field of nanomedicine research and development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nNDL6YYS6q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226287875.USD","LU1226288170.HKD","IE00BZ08YR35.GBP","LU1008478684.HKD","BK1515","LU1960683339.HKD","IE00BZ08YS42.EUR","IE00B543WZ88.USD","LU1152091754.HKD","LU0067412154.USD","LU1152091168.USD","IE0008368742.USD","LU0880133367.SGD","LU1226287792.SGD","LU0326950275.SGD","IE00B031HY20.USD","BK1521","BK1191","LU0140636845.USD","LU0501845795.SGD","LU1226288253.USD","IE00B5MMRT66.SGD","IE00BZ08YT58.USD","SG9999004220.SGD","LU1993786604.SGD","01093","LU1807302812.USD","IE0008369823.USD","LU1951186391.HKD","LU1226287529.USD","LU0072913022.USD"],"gpt_icon":0},{"id":"2545513864","title":"CSPC Pharmaceutical - Meloxicam Injection Obtains Drug Registration Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2545513864","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545513864?lang=en_us&edition=fundamental","pubTime":"2025-06-23 08:00","pubTimestamp":1750636859,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nFWN3SO00K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1226287529.USD","LU1008478684.HKD","BK1191","IE00BZ08YT58.USD","IE0008369823.USD","LU0326950275.SGD","IE00B031HY20.USD","LU1993786604.SGD","LU1226288253.USD","LU1152091754.HKD","01093","LU1226287792.SGD","BK1515","IE00B5MMRT66.SGD","LU0880133367.SGD","LU1807302812.USD","LU0072913022.USD","LU1152091168.USD","IE0008368742.USD","BK1521","LU0501845795.SGD","IE00BZ08YS42.EUR","LU0067412154.USD","IE00BZ08YR35.GBP","LU1951186391.HKD","SG9999004220.SGD","LU1226287875.USD","IE00B543WZ88.USD","LU0140636845.USD","LU1960683339.HKD","LU1226288170.HKD"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":36,"code":"91000000","status":"200"}]}}